Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls

On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]

ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs amid inflation, despite continued demand for sleep devices and masks. CEO Mick Farrell pointed to ongoing investments in innovation and supply chain efficiency as both a necessity and a source of margin challenges. Additionally, ResMed took a $42 million charge

Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.

ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...

In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.

Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.

ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

ResMed (NYSE:RMD) shares declined 5. 5% in premarket trading after the medical device manufacturer reported fourth-quarter fiscal 2026 results that delivered an earnings beat but fell slightly short on revenue.

ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.

Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.

ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46b for the period. See our latest analysis for ResMed. ResMed shares have climbed in recent weeks, with a 7 day share price return of 4.55% and a 90 day share price return of 8.28%. However, the year to date share price return is still down 8.49%, and the 1 year total shareholder return has...

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.

Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Viemed Healthcare (VMD) delivered earnings and revenue surprises of -30.00% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.

ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales a

SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.